Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, and was founded in 2002. Its shares trade on Nasdaq under the ticker ALNY. The shares are included in the Nasdaq-100 index.

Alnylam develops medicines based on RNA interference (RNAi) technology, which silences the production of disease-causing proteins at the genetic level. Its marketed products include Onpattro and Amvuttra for hereditary and cardiac amyloidosis, Givlaari for acute hepatic porphyria and Oxlumo for primary hyperoxaluria. A medicine the company has licensed is also marketed by Novartis as a cholesterol-lowering treatment. Its research pipeline includes candidates in cardiovascular and metabolic diseases and in the central nervous system.

Those following Alnylam stock typically watch the sales trend of its products, clinical study results, regulatory approval decisions and competition with other amyloidosis treatments. The Lzzo.com Alnylam Pharmaceuticals page brings the US dollars price, a price chart and technical indicators together on one screen.